stock-detail (HALO)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

4/23/2017 12:18 pm

4/23/2017 12:18 pm

4/23/2017 12:18 pm

4/23/2017 12:18 pm

4/23/2017 12:18 pm

4/21/2017 06:18 am

4/21/2017 06:18 am

4/21/2017 06:18 am

4/21/2017 06:18 am

4/21/2017 06:18 am

4/20/2017 12:18 pm

4/20/2017 12:18 pm

4/20/2017 12:18 pm

4/20/2017 12:18 pm

4/20/2017 12:18 pm

4/10/2017 12:17 pm

4/10/2017 12:17 pm

4/10/2017 12:17 pm

4/10/2017 12:17 pm

4/10/2017 12:17 pm

Halozyme's PEGPH20 Increases Immune Response and Effectiveness of Immunotherapies in Preclinical Cancer Models

4/3/2017 12:00 pm

[PR Newswire] - SAN DIEGO, April 3, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, demonstrated in preclinical models that ...

Rosetta Genomics and Halozyme Therapeutics: Wait for Better News

3/31/2017 01:03 pm

[Accesswire] - NEW YORK, NY / ACCESSWIRE / March 31, 2017 / Rosetta Genomics and Halozyme Therapeutics both posted losses in Thursday's trading session, on events that were outside of their control. Rosetta saw its earnings ...